Results 91 to 100 of about 8,451,399 (181)

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1258-1264, November 2026.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang   +3 more
wiley   +1 more source

Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing

open access: yes, 2018
The acquired and congenital forms of long QT syndrome represent 2 distinct but clinically and genetically intertwined disorders of cardiac repolarization characterized by the shared final common pathway of QT interval prolongation and risk of potentially
Michael J. Ackerman   +3 more
core   +1 more source

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, Volume 78, Issue 10, Page 1449-1466, October 2026.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Prevalence and risk factors for acquired long QT syndrome in the emergency department: a retrospective observational study. [PDF]

open access: yesWorld J Emerg Med, 2023
Fernandes DA   +7 more
europepmc   +1 more source

Ventricular Fibrillation Caused by a Low-Rate Pacemaker

open access: yesForbes Tıp Dergisi
After undergoing surgery for a perimembranous ventricular septal defect and discrete membrane resection, a 7-year-old patient developed complete atrioventricular block and received an epicardial pacemaker.
Hüseyin YILDIZ   +2 more
doaj   +1 more source

Charcot-Marie-Tooth type 1a in a child with Long QT syndrome

open access: yes, 2009
Charcot-Marie-Tooth disease (CMTD) is a hereditary demyelinating peripheral neuropathy clinically presenting with sensory and motor defects, but rarely affecting cardiac function.
S. G. Priori   +7 more
core   +1 more source

Electrocardiographic and Skin Manifestations of Turner Syndrome: Association With Cardiovascular Disease

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 10, Page 2234-2240, October 2026.
ABSTRACT Congenital heart disease (CHD) and dermatologic conditions such as lymphedema and acquired melanocytic nevi (AMN) are common in Turner Syndrome (TS). We hypothesized that abnormalities of cranial neural crest cell derivatives drive the skin and heart manifestations of TS. We conducted joint cardiac and skin examinations of volunteers at a 2023
Sarah Elsaim   +8 more
wiley   +1 more source

Pueraria mirifica, an estrogenic tropical herb, unveiled the severity of Type 1 LQTS caused by KCNQ1‐T587M

open access: yesJournal of Arrhythmia, 2021
Asami Kashiwa   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy